GBI Research, the leading
business intelligence provider, has released its latest research, "Major
Depressive Disorder Therapeutics in Major Developed Markets to 2020 - New
Launches and Modest Uptake of New Adjunctive Treatments to Offset Patent
Expiries", which provides insights into Major Depressive Disorder (MDD) in
the major developed markets of the US, the UK, France, Germany, Italy, Spain,
Japan and Canada. The report provides an estimation of market size for 2013,
along with market forecast until 2020. It also covers disease epidemiology,
treatment algorithms, treatment use patterns, in-depth analysis of the
pipeline, clinical trial failure rate and deal analysis for MDD. The report is
built using data and information sourced from proprietary databases, primary
and secondary research and in-house analysis carried out by GBI Research's team
of industry experts. In 2013, the value of the MDD therapeutics market in major
developed countries amounted to an estimated $8.7 billion. The market is
forecast to decline at a negative Compound Annual Growth Rate (CAGR) of 1.1%
between 2013 and 2020 to reach $8.1 billion. The decline is due to key patent
expiries of blockbuster drugs such as Lexapro, Cymbalta, Abilify, and Seroquel
XR during the forecast period. The expected launch of few promising pipeline
molecules such as brexpiprazole, cariprazine, ALKS-5461, GLYX-13 is likely to
offset the key patent expiries. Recently launched Brintellix which has a novel
multimodal mechanism of action and is the only drug which can provide
improvements in cognitive function is expected to lead the market by the end of
forecasting period.
View
Full Report with TOC @ http://www.radiantinsights.com/research/major-depressive-disorder-therapeutics-in-major-developed-markets-to-2020-new-launches-and-modest-uptake-of-new-adjunctive-treatments-to-offset-patent-expiries
Scope
The report analyzes treatment use
patterns, market characterization, pipeline analysis and key licensing and
co-development deals MDD in the major developed markets of the US, the UK,
France, Germany, Italy, Spain, Japan and Canada.The report includes -
- A brief introduction to MDD,
including the disease's pathophysiology, etiology, diagnosis and treatment
algorithms.
- In-depth analysis of currently
marketed drugs for MDD, including analysis of their safety, efficacy, treatment
patterns and strengths/weaknesses. Including a heat map comparing the drugs in
terms of safety and efficacy
- A
comprehensive review of the pipeline for MDD, including individual analysis of
a number of late-stage pipeline drugs that are likely to enter the market
during the forecast period. The pipeline is analyzed on the basis of phase
distribution, molecule types, program types, mechanisms of action and molecular
targets
About Radiant
Insights
Radiant
Insights is a platform for companies looking to meet their market research and
business intelligence requirements. We assist and facilitate organizations and
individuals procure market research reports, helping them in the decision
making process. We have a comprehensive collection of reports, covering over 40
key industries and a host of micro markets. In addition to over extensive
database of reports, our experienced research coordinators also offer a host of
ancillary services such as, research partnerships/ tie-ups and customized
research solutions.
For More
Information, Visit Radiant
Insights
Contact:
Michelle
Thoras
Corporate
Sales Specialist, USA
Radiant
Insights, Inc
Phone:
1-415-349-0054
Toll
Free: 1-888-202-9519
Email:
sales@radiantinsights.com
No comments:
Post a Comment